Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1933)	2/27/2008 11:05:18 AM
From: Jibacoa	Respond to of 3722

CVTX is down 17% on volume of 1,744,505 > its ADV bigcharts.marketwatch.com It reported yesterday its 4thQ results with a loss of $34.1M ($0.57/shr) vs. $68.1M ($1.18/shr) in 2006.Revenues were 77% better ($22.4M vs.12.7M) The cash & equivalents was $179.0M vs. $199.5M in Sep. It used $20.5 million in the 4thQ. As previously mentioned, the problem CVTX has with Ranexa is that some insurance companies have been reluctant to cover the drug or have it as a non-preferred treatment.If the FDA approves the change in labeling the sales of Ranexa should benefit as there are about 9M patients treated for angina mainly with generic drugs. I didn't listen at the C.C. yesterday, but apparently the people that did didn't liked it.<g> A replay is available by dialing (800) 642-1687 the PIN access number is 32378484. The recent short ratio was about 18x its ADV. The stock remains on its long DT coming from its Nov 200H at $93.13 <g> bigcharts.marketwatch.com Bernard